Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IV Zometa Clear all
Completed Not applicable Interventional Results available

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

NCT01205646
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronate therapy, PET Scan
Drug · Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 11, 2026, 2:16 AM EDT
Terminated Not applicable Interventional Results available

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid

NCT01772719
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Simvastatin and zoledronic acid
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 11, 2026, 2:16 AM EDT
Terminated Not applicable Interventional Results available

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

NCT01409811
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 1 Interventional

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

NCT00741377
View directory record Official record
Conditions
Multiple Myeloma Bone Disease
Interventions
BHQ880, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 4 Interventional

Non-small Cell Lung Cancer Registry

NCT00099541
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
101
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Anaheim, California + 93 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2009 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 4 Interventional Results available

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

NCT00927186
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Teriparatide, Zoledronic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 89 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Lakewood, Colorado • Atlanta, Georgia • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 11, 2026, 2:16 AM EDT
Active, not recruiting Phase 2 Interventional

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

NCT03073785
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy, Zoledronic Acid
Drug · Other · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 1Phase 2 Interventional

Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

NCT00060138
View directory record Official record
Conditions
Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
Interventions
monoclonal antibody CAL, zoledronic acid
Biological · Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Sep 11, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional Results available

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

NCT02516423
View directory record Official record
Conditions
Solitary Osseous Plasmacytoma
Interventions
ixazomib, lenalidomide, dexamethasone, zoledronic acid
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
388
States / cities
Anchorage, Alaska • Burbank, California • Clovis, California + 267 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NCT00436917
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid, Letrozole as adjuvant therapy
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 11, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional

A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain

NCT00099177
View directory record Official record
Conditions
Pain, Bone Neoplasm, Neoplasm Metastasis
Interventions
ibandronate [Bondronat], zoledronic acid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Miami, Florida • Macon, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women

NCT00361595
View directory record Official record
Conditions
Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Up to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

NCT00566618
View directory record Official record
Conditions
Breast Cancer, Bone Metastases
Interventions
Dasatinib, Zoledronic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 11, 2026, 2:16 AM EDT
Withdrawn Not applicable Interventional

Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid

NCT02069340
View directory record Official record
Conditions
Malignant Neoplasm, Musculoskeletal Complications
Interventions
zoledronic acid, pharmacological study
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women

NCT01721993
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
T121, Zoledronic acid
Drug
Lead sponsor
Thar Pharmaceuticals, Inc
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

NCT00039104
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
rebimastat, zoledronic acid, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 11, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

NCT00582790
View directory record Official record
Conditions
Kidney Cancer
Interventions
IL2, Zoledronic acid
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 11, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer

NCT01004510
View directory record Official record
Conditions
Malignant Pleural Effusion, Non Small Cell Lung Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Peter Bushunow MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Sep 11, 2026, 2:16 AM EDT
Recruiting Phase 1 Interventional

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

NCT02508038
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Rhabdomyosarcoma, Ewing Sarcoma, Primitive Neuroectodermal Tumor, Osteosarcoma, Neuroblastoma
Interventions
TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
7 Months to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 11, 2026, 2:16 AM EDT
Recruiting No phase listed Observational

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

NCT03958565
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tyrosine Kinase Inhibitor, Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA], Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Biological · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

NCT01204203
View directory record Official record
Conditions
Mesothelioma
Interventions
Zometa
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

NCT00079001
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
238
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 159 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 11, 2026, 2:16 AM EDT
Completed No phase listed Observational

Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis

NCT00264082
View directory record Official record
Conditions
Breast Cancer
Interventions
Zometa(drug)
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 11, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Results available

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

NCT00742924
View directory record Official record
Conditions
Sarcoma
Interventions
cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, zoledronic acid, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, filgrastim, Mesna
Drug · Procedure · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Sep 11, 2026, 2:16 AM EDT